-
1
-
-
1842584776
-
Newest findings on the oldest oncogene; How activated src does it
-
Frame MC,. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989-998.
-
(2004)
J Cell Sci
, vol.117
, pp. 989-998
-
-
Frame, M.C.1
-
2
-
-
7944236785
-
Src family kinases, key regulators of signal transduction
-
Parsons SJ, Parsons JT,. Src family kinases, key regulators of signal transduction. Oncogene 2004; 23: 7906-7909.
-
(2004)
Oncogene
, vol.23
, pp. 7906-7909
-
-
Parsons, S.J.1
Parsons, J.T.2
-
3
-
-
0038386613
-
Src family kinases in tumor progression and metastasis
-
Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358.
-
(2003)
Cancer Metastasis Rev
, vol.22
, pp. 337-358
-
-
Summy, J.M.1
Gallick, G.E.2
-
4
-
-
51449088226
-
Src and focal adhesion kinase as therapeutic targets in cancer
-
Brunton VG, Frame MC,. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008; 8: 427-432.
-
(2008)
Curr Opin Pharmacol
, vol.8
, pp. 427-432
-
-
Brunton, V.G.1
Frame, M.C.2
-
5
-
-
77956042544
-
SRC: A century of science brought to the clinic
-
Aleshin A, Finn RS,. SRC: a century of science brought to the clinic. Neoplasia 2010; 12: 599-607.
-
(2010)
Neoplasia
, vol.12
, pp. 599-607
-
-
Aleshin, A.1
Finn, R.S.2
-
6
-
-
84861491693
-
Src kinase inhibitors: Promising cancer therapeutics?
-
Creedon H, Brunton VG,. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 2012; 17: 145-159.
-
(2012)
Crit Rev Oncog
, vol.17
, pp. 145-159
-
-
Creedon, H.1
Brunton, V.G.2
-
7
-
-
77954690732
-
Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
-
Mayer EL, Krop IE,. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526-3532.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3526-3532
-
-
Mayer, E.L.1
Krop, I.E.2
-
8
-
-
73549112454
-
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
-
Elsberger B, Tan BA, Mitchell TJ, et al,. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009; 175: 1389-1397.
-
(2009)
Am J Pathol
, vol.175
, pp. 1389-1397
-
-
Elsberger, B.1
Tan, B.A.2
Mitchell, T.J.3
-
9
-
-
79959362334
-
Clinicopathological significance of Y416Src and Y527Src expression in breast cancer
-
Kanomata N, Kurebayashi J, Kozuka Y, et al,. Clinicopathological significance of Y416Src and Y527Src expression in breast cancer. J Clin Pathol 2011; 64: 578-586.
-
(2011)
J Clin Pathol
, vol.64
, pp. 578-586
-
-
Kanomata, N.1
Kurebayashi, J.2
Kozuka, Y.3
-
10
-
-
8344223854
-
Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: Implications for cell proliferation
-
Shupnik MA,. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004; 23: 7979-7989.
-
(2004)
Oncogene
, vol.23
, pp. 7979-7989
-
-
Shupnik, M.A.1
-
11
-
-
79959249550
-
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
-
Chen Y, Alvarez EA, Azzam D, et al,. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011; 128: 69-78.
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 69-78
-
-
Chen, Y.1
Alvarez, E.A.2
Azzam, D.3
-
12
-
-
66149160364
-
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors
-
Chen Y, Guggisberg N, Jorda M, et al,. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009; 15: 3396-3405.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3396-3405
-
-
Chen, Y.1
Guggisberg, N.2
Jorda, M.3
-
13
-
-
33846235881
-
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
-
Herynk MH, Beyer AR, Cui Y, et al,. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006; 5: 3023-3031.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 3023-3031
-
-
Herynk, M.H.1
Beyer, A.R.2
Cui, Y.3
-
14
-
-
33846870586
-
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
-
Hiscox S, Morgan L, Green T, et al,. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006; 13 (Suppl 1): S53-S59.
-
(2006)
Endocr Relat Cancer
, vol.13
, Issue.SUPPL. 1
-
-
Hiscox, S.1
Morgan, L.2
Green, T.3
-
15
-
-
82955234094
-
Significance of ER-Src axis in hormonal therapy resistance
-
Vallabhaneni S, Nair BC, Cortez V, et al,. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat 2011; 130: 377-385.
-
(2011)
Breast Cancer Res Treat
, vol.130
, pp. 377-385
-
-
Vallabhaneni, S.1
Nair, B.C.2
Cortez, V.3
-
16
-
-
4544235743
-
C-Src and cooperating partners in human cancer
-
Ishizawar R, Parsons SJ,. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214.
-
(2004)
Cancer Cell
, vol.6
, pp. 209-214
-
-
Ishizawar, R.1
Parsons, S.J.2
-
17
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, et al,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
18
-
-
79953745096
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
-
Zhang S, Huang WC, Li P, et al,. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Med 2011; 17: 461-469.
-
(2011)
Nature Med
, vol.17
, pp. 461-469
-
-
Zhang, S.1
Huang, W.C.2
Li, P.3
-
19
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
Lombardo LJ, Lee FY, Chen P, et al,. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
-
(2004)
J Med Chem
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
20
-
-
34548701082
-
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro
-
Finn RS, Dering J, Ginther C, et al,. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
-
(2007)
Breast Cancer Res Treat
, vol.105
, pp. 319-326
-
-
Finn, R.S.1
Dering, J.2
Ginther, C.3
-
21
-
-
33947225176
-
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
-
Huang F, Reeves K, Han X, et al,. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226-2238.
-
(2007)
Cancer Res
, vol.67
, pp. 2226-2238
-
-
Huang, F.1
Reeves, K.2
Han, X.3
-
22
-
-
33846241683
-
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
-
Serrels A, Macpherson IR, Evans TR, et al,. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-3022.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 3014-3022
-
-
Serrels, A.1
Macpherson, I.R.2
Evans, T.R.3
-
23
-
-
33745243692
-
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
-
Song L, Morris M, Bagui T, et al,. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-5548.
-
(2006)
Cancer Res
, vol.66
, pp. 5542-5548
-
-
Song, L.1
Morris, M.2
Bagui, T.3
-
24
-
-
56449100212
-
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells
-
Buettner R, Mesa T, Vultur A, et al,. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008; 6: 1766-1774.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 1766-1774
-
-
Buettner, R.1
Mesa, T.2
Vultur, A.3
-
25
-
-
77953898050
-
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma
-
Morton JP, Karim SA, Graham K, et al,. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010; 139: 292-303.
-
(2010)
Gastroenterology
, vol.139
, pp. 292-303
-
-
Morton, J.P.1
Karim, S.A.2
Graham, K.3
-
26
-
-
27144547509
-
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
-
Nam S, Kim D, Cheng JQ, et al,. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189.
-
(2005)
Cancer Res
, vol.65
, pp. 9185-9189
-
-
Nam, S.1
Kim, D.2
Cheng, J.Q.3
-
27
-
-
66149164441
-
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer
-
Tatarov O, Mitchell TJ, Seywright M, et al,. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3540-3549
-
-
Tatarov, O.1
Mitchell, T.J.2
Seywright, M.3
-
28
-
-
44849134528
-
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
-
Park SI, Zhang J, Phillips KA, et al,. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-3333.
-
(2008)
Cancer Res
, vol.68
, pp. 3323-3333
-
-
Park, S.I.1
Zhang, J.2
Phillips, K.A.3
-
29
-
-
33644647192
-
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
-
Trevino JG, Summy JM, Lesslie DP, et al,. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-972.
-
(2006)
Am J Pathol
, vol.168
, pp. 962-972
-
-
Trevino, J.G.1
Summy, J.M.2
Lesslie, D.P.3
-
30
-
-
80455173400
-
Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study
-
Finn RS, Bengala C, Ibrahim N, et al,. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17: 6905-6913.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6905-6913
-
-
Finn, R.S.1
Bengala, C.2
Ibrahim, N.3
-
31
-
-
80455132309
-
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
-
Mayer EL, Baurain JF, Sparano J, et al,. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17: 6897-6904.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6897-6904
-
-
Mayer, E.L.1
Baurain, J.F.2
Sparano, J.3
-
32
-
-
0034724314
-
Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
-
Andrechek ER, Hardy WR, Siegel PM, et al,. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A 2000; 97: 3444-3449.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 3444-3449
-
-
Andrechek, E.R.1
Hardy, W.R.2
Siegel, P.M.3
-
33
-
-
42049084166
-
Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis
-
Dourdin N, Schade B, Lesurf R, et al,. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008; 68: 2122-2131.
-
(2008)
Cancer Res
, vol.68
, pp. 2122-2131
-
-
Dourdin, N.1
Schade, B.2
Lesurf, R.3
-
34
-
-
0037136697
-
Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency
-
Gallagher RC, Hay T, Meniel V, et al,. Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency. Oncogene 2002; 21: 6446-6457.
-
(2002)
Oncogene
, vol.21
, pp. 6446-6457
-
-
Gallagher, R.C.1
Hay, T.2
Meniel, V.3
-
35
-
-
0032171148
-
Efficient BLG-Cre mediated gene deletion in the mammary gland
-
Selbert S, Bentley DJ, Melton DW, et al,. Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res 1998; 7: 387-396.
-
(1998)
Transgenic Res
, vol.7
, pp. 387-396
-
-
Selbert, S.1
Bentley, D.J.2
Melton, D.W.3
-
36
-
-
0036714806
-
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
-
Li G, Robinson GW, Lesche R, et al,. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-4170.
-
(2002)
Development
, vol.129
, pp. 4159-4170
-
-
Li, G.1
Robinson, G.W.2
Lesche, R.3
-
37
-
-
65549088630
-
Tracing pathway activities with kinase inhibitors and reverse phase protein arrays
-
van Oostrum J, Calonder C, Rechsteiner D, et al,. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl 2009; 3: 412-422.
-
(2009)
Proteomics Clin Appl
, vol.3
, pp. 412-422
-
-
Van Oostrum, J.1
Calonder, C.2
Rechsteiner, D.3
-
38
-
-
0037103985
-
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors
-
Miyoshi K, Rosner A, Nozawa M, et al,. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002; 21: 5548-5556.
-
(2002)
Oncogene
, vol.21
, pp. 5548-5556
-
-
Miyoshi, K.1
Rosner, A.2
Nozawa, M.3
-
39
-
-
0037039355
-
Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias
-
Miyoshi K, Shillingford JM, Le Provost F, et al,. Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A 2002; 99: 219-224.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 219-224
-
-
Miyoshi, K.1
Shillingford, J.M.2
Le Provost, F.3
-
40
-
-
51849140016
-
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor
-
Luo FR, Barrett YC, Yang Z, et al,. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008; 62: 1065-1074.
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 1065-1074
-
-
Luo, F.R.1
Barrett, Y.C.2
Yang, Z.3
-
41
-
-
78549246804
-
Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: Effects on E-cadherin dynamics
-
Canel M, Serrels A, Miller D, et al,. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 2010; 70: 9413-9422.
-
(2010)
Cancer Res
, vol.70
, pp. 9413-9422
-
-
Canel, M.1
Serrels, A.2
Miller, D.3
-
42
-
-
66149100509
-
Real-time study of E-cadherin and membrane dynamics in living animals: Implications for disease modeling and drug development
-
Serrels A, Timpson P, Canel M, et al,. Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development. Cancer Res 2009; 69: 2714-2719.
-
(2009)
Cancer Res
, vol.69
, pp. 2714-2719
-
-
Serrels, A.1
Timpson, P.2
Canel, M.3
-
43
-
-
0029097471
-
Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene
-
Webster MA, Cardiff RD, Muller WJ,. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci U S A 1995; 92: 7849-7853.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 7849-7853
-
-
Webster, M.A.1
Cardiff, R.D.2
Muller, W.J.3
-
44
-
-
84857402960
-
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis
-
Marcotte R, Smith HW, Sanguin-Gendreau V, et al,. Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci U S A 2012; 109: 2808-2813.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 2808-2813
-
-
Marcotte, R.1
Smith, H.W.2
Sanguin-Gendreau, V.3
-
45
-
-
78751642736
-
Control of mammary tumor differentiation by SKI-606 (bosutinib)
-
Hebbard L, Cecena G, Golas J, et al,. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene 2011; 30: 301-312.
-
(2011)
Oncogene
, vol.30
, pp. 301-312
-
-
Hebbard, L.1
Cecena, G.2
Golas, J.3
-
46
-
-
60149091984
-
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
-
Serrels B, Serrels A, Mason SM, et al,. A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis 2009; 30: 249-257.
-
(2009)
Carcinogenesis
, vol.30
, pp. 249-257
-
-
Serrels, B.1
Serrels, A.2
Mason, S.M.3
-
47
-
-
33847728182
-
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
-
Jallal H, Valentino ML, Chen G, et al,. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588.
-
(2007)
Cancer Res
, vol.67
, pp. 1580-1588
-
-
Jallal, H.1
Valentino, M.L.2
Chen, G.3
-
48
-
-
26444468152
-
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
-
Johnson FM, Saigal B, Talpaz M, et al,. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-6932.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6924-6932
-
-
Johnson, F.M.1
Saigal, B.2
Talpaz, M.3
-
49
-
-
67649846431
-
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
-
Pichot CS, Hartig SM, Xia L, et al,. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101: 38-47.
-
(2009)
Br J Cancer
, vol.101
, pp. 38-47
-
-
Pichot, C.S.1
Hartig, S.M.2
Xia, L.3
-
50
-
-
34047265691
-
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival
-
Shor AC, Keschman EA, Lee FY, et al,. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67: 2800-2808.
-
(2007)
Cancer Res
, vol.67
, pp. 2800-2808
-
-
Shor, A.C.1
Keschman, E.A.2
Lee, F.Y.3
-
51
-
-
33644532202
-
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling
-
Coluccia AM, Benati D, Dekhil H, et al,. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006; 66: 2279-2286.
-
(2006)
Cancer Res
, vol.66
, pp. 2279-2286
-
-
Coluccia, A.M.1
Benati, D.2
Dekhil, H.3
-
52
-
-
0028174305
-
Involvement of pp60c-src with two major signaling pathways in human breast cancer
-
Luttrell DK, Lee A, Lansing TJ, et al,. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 1994; 91: 83-87.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 83-87
-
-
Luttrell, D.K.1
Lee, A.2
Lansing, T.J.3
-
53
-
-
0029165834
-
Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor
-
Muthuswamy SK, Muller WJ,. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 1995; 11: 271-279.
-
(1995)
Oncogene
, vol.11
, pp. 271-279
-
-
Muthuswamy, S.K.1
Muller, W.J.2
-
54
-
-
0028047315
-
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity
-
Muthuswamy SK, Siegel PM, Dankort DL, et al,. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-743.
-
(1994)
Mol Cell Biol
, vol.14
, pp. 735-743
-
-
Muthuswamy, S.K.1
Siegel, P.M.2
Dankort, D.L.3
-
55
-
-
0035932351
-
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
-
Belsches-Jablonski AP, Biscardi JS, Peavy DR, et al,. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001; 20: 1465-1475.
-
(2001)
Oncogene
, vol.20
, pp. 1465-1475
-
-
Belsches-Jablonski, A.P.1
Biscardi, J.S.2
Peavy, D.R.3
-
56
-
-
27844600580
-
The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: Implications for ErbB-2 mediated signaling and transformation
-
Kim H, Chan R, Dankort DL, et al,. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene 2005; 24: 7599-7607.
-
(2005)
Oncogene
, vol.24
, pp. 7599-7607
-
-
Kim, H.1
Chan, R.2
Dankort, D.L.3
-
57
-
-
70350539312
-
C-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential
-
Marcotte R, Zhou L, Kim H, et al,. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009; 29: 5858-5871.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 5858-5871
-
-
Marcotte, R.1
Zhou, L.2
Kim, H.3
-
58
-
-
33745230142
-
Role of SRC kinases in Neu-induced tumorigenesis: Challenging the paradigm using Csk homologous kinase transgenic mice
-
Kaminski R, Zagozdzon R, Fu Y, et al,. Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. Cancer Res 2006; 66: 5757-5762.
-
(2006)
Cancer Res
, vol.66
, pp. 5757-5762
-
-
Kaminski, R.1
Zagozdzon, R.2
Fu, Y.3
-
59
-
-
77952114407
-
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
-
Moulder S, Yan K, Huang F, et al,. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010; 9: 1120-1127.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1120-1127
-
-
Moulder, S.1
Yan, K.2
Huang, F.3
-
60
-
-
84859964339
-
Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
-
Garcia-Gomez A, Ocio EM, Crusoe E, et al,. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One 2012; 7: e34914.
-
(2012)
PLoS One
, vol.7
-
-
Garcia-Gomez, A.1
Ocio, E.M.2
Crusoe, E.3
-
61
-
-
77953229623
-
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
-
Lee YC, Huang CF, Murshed M, et al,. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29: 3196-3207.
-
(2010)
Oncogene
, vol.29
, pp. 3196-3207
-
-
Lee, Y.C.1
Huang, C.F.2
Murshed, M.3
-
62
-
-
33751028441
-
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
-
Wilson GR, Cramer A, Welman A, et al,. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006; 95: 1410-1414.
-
(2006)
Br J Cancer
, vol.95
, pp. 1410-1414
-
-
Wilson, G.R.1
Cramer, A.2
Welman, A.3
-
63
-
-
31544460437
-
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression
-
Diaz N, Minton S, Cox C, et al,. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 20-28
-
-
Diaz, N.1
Minton, S.2
Cox, C.3
-
64
-
-
0036890288
-
Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma
-
Ito Y, Kawakatsu H, Takeda T, et al,. Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat 2002; 76: 261-267.
-
(2002)
Breast Cancer Res Treat
, vol.76
, pp. 261-267
-
-
Ito, Y.1
Kawakatsu, H.2
Takeda, T.3
-
65
-
-
29044442658
-
Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma
-
Madan R, Smolkin MB, Cocker R, et al,. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol 2006; 37: 9-15.
-
(2006)
Hum Pathol
, vol.37
, pp. 9-15
-
-
Madan, R.1
Smolkin, M.B.2
Cocker, R.3
-
66
-
-
84857923923
-
Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence
-
Han K, Nofech-Mozes S, Narod S, et al,. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 2012; 24: 183-189.
-
(2012)
Clin Oncol (R Coll Radiol)
, vol.24
, pp. 183-189
-
-
Han, K.1
Nofech-Mozes, S.2
Narod, S.3
-
67
-
-
0033549344
-
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
-
Fisher B, Dignam J, Wolmark N, et al,. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
-
(1999)
Lancet
, vol.353
, pp. 1993-2000
-
-
Fisher, B.1
Dignam, J.2
Wolmark, N.3
|